Tirzepatide Officially Off FDA's Shortage List

(MedPage Today) -- The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA announced Thursday.
As a result, compounders will have a grace period of 60 to 90 days to wrap up production and...